Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using<i>in silico</i>clinical trials-Reference-Cited by-同舟云学术

Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles usingin silicoclinical trials

Published:2022-06 Issue:2 Volume:2 Page:
ISSN:2689-9655
Container-title:Computational and Systems Oncology
language:en
Short-container-title:Comp Sys Onco

Author:

Cardinal Olivia¹,Burlot Chloé¹,Fu Yangxin²,Crosley Powel²^ORCID,Hitt Mary²,Craig Morgan¹³^ORCID,Jenner Adrianne L.¹³⁴

Affiliation:

1. Department of Mathematics and Statistics Université de Montréal Montréal Quebec Canada

2. Department of Oncology University of Alberta Edmonton Alberta Canada

3. Research Centre Sainte‐Justine University Hospital Montréal Quebec Canada

4. School of Mathematical Sciences Queensland University of Technology Brisbane Queensland

Funder

Natural Sciences and Engineering Research Council of Canada

Publisher

Wiley

Subject

Industrial and Manufacturing Engineering,Polymers and Plastics,Business and International Management

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cso2.1035

Reference49 articles.

1. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

2. Ovarian cancer

3. Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro

4. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy

5. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling;npj Digital Medicine;2024-07-16

2. In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients;CPT: Pharmacometrics & Systems Pharmacology;2024-02-07

3. Deconstructing the Contributions of Heterogeneity to Combination Treatment of Hormone-Sensitive Breast Cancer;The IMA Volumes in Mathematics and its Applications;2024

4. Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary;Cancer Biology & Therapy;2023-11-27

5. Quantifying assays: inhibition of signalling pathways of cancer;Mathematical Medicine and Biology: A Journal of the IMA;2023-09